SGHT:NASDAQ, Sight Sciences, Inc.
SGHT stock overview
Sight Sciences, Inc. (SGHT:NASDAQ) closed at $8.88 on October 15, 2026,
up 7.64% on the day.
The stock trades 8.6% below its 52-week high of $9.71
and 163.5% above its 52-week low of $3.37.
Over the past year, it gained 129.2%.
Sight Sciences, Inc. is part of the Health Care sector.
Key figures
- Price
- $8.88
- Day change
- +7.64%
- Volume
- 142,699
- Average volume
- 272,429
- Market cap
- 489M+
- 52-week range
- $3.37 – $9.71
- 50-day average
- $8.32
- 200-day average
- $5.90
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -7.98% |
+1.73% |
+64.02% |
+89.22% |
+129.17% |
Price action over the past year
In 252 trading sessions since October 14, 2025, SGHT closed higher on 123 days (49%).
Its best day was October 17, 2025 (+35.94%) and its worst was March 5, 2026 (-26.80%).
The stock moved 10% or more in a single session 8 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
SGHT news
-
Oct 8, 2026:
Sight Sciences (SGHT) Stock Gets Fair Value Boost After Analyst Target Increases
-
Oct 1, 2026:
Sight Sciences to Debut the OMNI Ultra Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
-
Oct 1, 2026:
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
-
Sep 1, 2026:
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
-
Aug 20, 2026:
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
-
Aug 19, 2026:
Sector Update: Healthcare Stocks Gain Wednesday Afternoon
-
Aug 19, 2026:
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
-
Aug 12, 2026:
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript
About Sight Sciences, Inc.
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company's product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company's non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Find more stocks like SGHT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.